360° SearchNetwork Hot Spots Trends Time Series

HuCAL

Type: Product

Name: HuCAL

First reported May 08 2013 - Updated May 08 2013 - 1 reports

MorphoSys to Present at Four Investor Conferences in May Marketwired

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwired - May 8, 2013) - MorphoSys AG / MorphoSys to Present at Four Investor Conferences in May . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this ... [Published Yahoo! Finance - May 08 2013]

Entities: MorphoSys AG, Antibody, HuCAL

First reported May 08 2013 - Updated May 08 2013 - 1 reports

MorphoSys to Present at Four Investor Conferenc...

MorphoSys AG / MorphoSys to Present at Four Investor Conferences in May . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.The management of MorphoSys AG (FSE: MOR; Prime Standard ... [Published Best Invest - May 08 2013]

Entities: MorphoSys AG, Antibody, Simon Moroney, Claudia Gutjahr-Löser

First reported May 03 2013 - Updated May 03 2013 - 1 reports

MorphoSys Reports Profit In Q1; Re-confirms 2013 Guidance - Quick Facts

MorphoSys AG (MPSYY.PK) reported first-quarter profit before interest and taxes, or EBIT, from continued operations of 2.5 million euros, compared to a loss of 0.7 million euros last year. Profit from continuing operations was 1.9 million euros or 0.08 ... [Published RTTNews.com - May 03 2013]

Entities: MorphoSys AG, Continuing Operations, EBIT, Diagnostic

First reported May 02 2013 - Updated May 02 2013 - 1 reports

MorphoSys Announces Clinical Milestone in Ophthalmology Program Thomson Reuters ONE

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has received a milestone payment from Novartis in connection with the clinical trial application (CTA/IND) and projected initiation of a Phase 1 clinical trial. The HuCAL-derived, ... [Published Yahoo! Finance - May 02 2013]

Entities: MorphoSys AG, Antibody, Ophthalmology, Phase I

First reported May 02 2013 - Updated May 02 2013 - 1 reports

MorphoSys Announces Clinical Milestone in Ophth...

Entities: MorphoSys AG, Antibody, Phase I

First reported May 02 2013 - Updated May 02 2013 - 1 reports

MorphoSys Announces Clinical Milestone in Ophthalmology Program

Entities: MorphoSys AG, Antibody, Ophthalmology, Phase I

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

MorphoSys AG

MorphoSys to Present at Kempen & Co's Life Sciences & Healthcare Conference Thomson Reuters ONE

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will present at Kempen & Co`s 6th Life Sciences & Healthcare Conference: Kempen & Co`s 6th Life Sciences & Healthcare ConferenceDate:$ $ April 23, 2013Venue:$ ... [Published Yahoo! Finance - Apr 22 2013]

Entities: MorphoSys AG, Healthcare Conference, Life Science

First reported Apr 16 2013 - Updated Apr 16 2013 - 2 reports

MorphoSys AG: Announcement of the Convening of the AGM in Mu. . .

MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on 4 June 2013 according to sec. 121 para. 4a AktG with the objective of Europe-wide distributionMarketwireMARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwired) -- 04/16/13 ... [Published Equities.com - Apr 16 2013]

Entities: MorphoSys AG, HuCAL, Antibody

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

MorphoSys AG: Announcement of the Convening of ...

MorphoSys AG / MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on 4 June 2013 according to sec. 121 para. 4a AktG with the objective of Europe-wide distribution . Processed and transmitted by Thomson Reuters ONE. The issuer is ... [Published Best Invest - Apr 16 2013]

Entities: MorphoSys AG, Antibody, Fiscal Year, HuCAL

First reported Dec 21 2012 - Updated Dec 21 2012 - 1 reports

Deals Of The Week: 'Tis The Season To Be Jolly

'Tis the Season to be Jolly, so deals of the week has finalized its last offering of the year, confident that dire warnings of apocalypse coinciding with the ending of a Mayan calendar are hokum.Business development executives are also ignoring such ... [Published The IN VIVO Blog - Dec 21 2012]

Entities: Antibody, Merck & Co Inc, Celgene Corporation

First reported Dec 17 2012 - Updated Dec 17 2012 - 1 reports

MorphoSys to sell research and diagnostic antibody business AbD Serotec to Bio-Rad for Euro 53 million

MorphoSys AG, a leading biotechnology companies focusing on fully human antibodies, has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science ... [Published PharmaBiz - Dec 17 2012]

Entities: MorphoSys AG, AbD Serotec, Bio-Rad Laboratories Incorporated, Diagnostic, Antibody

First reported Dec 08 2012 - Updated Dec 08 2012 - 1 reports

MorphoSys' anti-CD38 cancer programme MOR202 receives US patent

The US Patent and Trademark Office (USPTO) has granted a patent covering the MorphoSys' cancer compound MOR202. The new patent (US 8,263,746) covers functional properties of anti-CD38 antibodies and provides additional patent protection for MorphoSys's ... [Published PharmaBiz - Dec 08 2012]

Entities: Patent, MorphoSys AG, Antibody

Quotes

...Arndt Schottelius, Chief Development Officer of MorphoSys AG. "Broadening the drug's development program into additional indications is intended to maximize the value of this compound."

MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma [Published Zecco - May 13 2013]

...Thearticletitled "A fully synthetic human Fab antibody library based on fixedVH/VLframework pairings with favorable biophysical properties" describesfor thefirst time the detailed design, generation and testing of the Ylanthialibrary...

MorphoSys Announces First Scientific Publication on Novel A. . . [Published Equities.com - May 10 2013]

...Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "In total, our collaboration with Novartis has resulted in seven clinical programs to date, three currently being in Phase 1 and four in Phase 2."

MorphoSys Announces Clinical Milestone in Ophthalmology Program Thomson Reuters ONE [Published Yahoo! Finance - May 02 2013]

"Tis the Season to be Jolly, so deals of the week has finalized its last offering of the year, confident that dire warnings of apocalypse coinciding with the ending of a Mayan calendar are hokum.Business development executives are also ignoring such suspect perils, and are continuing to close on deals, collaborations and tie-ups, producing their own version of Christmas Cheer.Europe is one region where holly bedecked halls will hopefully take the mind off austerity and its continuing toll on individuals" livelihoods and the funding of health care. At least no European country has succumbed to defaulting on their debts, yet...

Deals Of The Week: 'Tis The Season To Be Jolly [Published The IN VIVO Blog - Dec 21 2012]

More Content

sort by: Date \| Relevance
MorphoSys Initiates Phase 2 Study of Anti-CD19 ... [Published Zecco - May 13 2013]
MorphoSys Announces First Scientific Publicatio... [Published Equities.com - May 10 2013]
MorphoSys Announces First Scientific Publicatio... [Published Live-PR.com - May 10 2013]
MorphoSys to Present at Four Investor Conferenc... [Published Presscontacts.com - May 08 2013]
MorphoSys to Present at Four Investor Conferenc... [Published Yahoo! Finance - May 08 2013]
MORPHOSYS AG: to Present at Four Investor Confe... [Published 4 Traders - May 08 2013]
MorphoSys AG: MorphoSys to Present at Four Inve... [Published FinanzNachrichten.de - May 08 2013]
MorphoSys to Present at Four Investor Conferenc... [Published Best Invest - May 08 2013]
MorphoSys Reports Profit In Q1; Re-confirms 201... [Published RTTNews.com - May 03 2013]
MorphoSys Announces Clinical Milestone in Ophth... [Published Yahoo! Finance - May 02 2013]
MorphoSys AG : MorphoSys Announces Clinical Mil... [Published Investegate - May 02 2013]
MorphoSys Announces Clinical Milestone in Ophth... [Published MoneyAM - May 02 2013]
MorphoSys Announces Clinical Milestone in Ophth... [Published Zecco - May 02 2013]
MorphoSys to Present at Kempen & Co's Life Scie... [Published Yahoo! Finance - Apr 22 2013]
MorphoSys AG: Announcement of the Convening of ... [Published Equities.com - Apr 16 2013]
MorphoSys AG : MorphoSys AG: Announcement of th... [Published Investegate - Apr 16 2013]
MorphoSys AG: Announcement of the Convening of ... [Published Interest!ALERT - Apr 16 2013]
MorphoSys AG: Announcement of the Convening of ... [Published Saudi Fransi Capital - Apr 16 2013]
MorphoSys AG: Announcement of the Convening of ... [Published Best Invest - Apr 16 2013]
MorphoSys completes sale of research and diagno... [Published PharmaBiz - Jan 12 2013]
Deals Of The Week: 'Tis The Season To Be Jolly [Published The IN VIVO Blog - Dec 21 2012]
MorphoSys to sell research and diagnostic antib... [Published PharmaBiz - Dec 17 2012]
MorphoSys' anti-CD38 cancer programme MOR202 re... [Published PharmaBiz - Dec 08 2012]

Blogs

sort by: Date \| Relevance
Deals Of The Week: 'Tis The Season To Be Jolly [Published The IN VIVO Blog - Dec 21 2012] 'Tis the Season to be Jolly, so deals of the week has finalized its last offering of the year, confident that dire warnings of apocalypse coinciding with the ending of a Mayan calendar are hokum.Business development executives are also ignoring such ...